TABLE 3.
Treatment (μM) | Relative survival (%)a |
||
---|---|---|---|
No plasmid | pSPOK-gyrA | pDrive-gyrA | |
No treatment | 100 | 96 | 98 |
Nalidixic acid | |||
100 | 55 | 57 | 15 |
300 | 30 | 56 | NT |
400 | 8 | 33 | NT |
Norfloxacin | |||
0.5 | 64 | 82 | 3 |
1.25 | 20 | 51 | NT |
1.5 | 5 | 13 | NT |
Chloramphenicol | |||
7 | 88 | 100 | 45 |
42 | 48 | 100 | NT |
70 | 28 | 75 | NT |
Tetracycline | |||
1 | 90 | 100 | 37 |
2 | 53 | 100 | NT |
6 | 14 | 50 | NT |
NT, not tested. pSPOK-gyrA, overexpression of GyrA; pDrive-gyrA, reduced expression of GyrA.